Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy US biotech Halda Therapeutics and its RIPTAC platform for generating small-molecule cancer drugs. J&J said it ...

HGR Construction donates 35,000 pounds of food after team competition for Share Your Christmas Trump expected to sign executive order to reclassify marijuana as soon as Monday, source tells CNBC; pot ...

Sushi of Gari 46 was hit with an employment retaliation lawsuit on Nov. 25 in New York Southern District Court. The action, brought by Lipsky Lowe on behalf of a former manager, alleges the restaurant ...

Neeg Australia feem coob ces yeej khwv tau nyiaj los ntawm tej hauj lwm lawv ua xwb, tab sis cov kev nqes peev lagluam kuj yog ib co xub ke uas pab kom coob leej ntau tus khwv tau nyiaj thiab. Mloog ...

Johnson & Johnson acquires Halda Therapeutics for $3 billion to strengthen its oncology portfolio, focusing on prostate cancer therapies. The acquisition includes HLD-0915, a clinical-stage therapy ...

Nov 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand its presence in treatments ...

(RTTNews) - Johnson & Johnson (JNJ) announced Monday that it has entered into a definitive agreement to acquire biotechnology company Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. Halda is ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while strengthening its prostate cancer franchise built on Erleada. At the center of the ...

(Reuters) -Johnson & Johnson said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand its presence in treatments targeting solid tumors and prostate ...

Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical development Additional RIPTAC™ programs in development for ...